Schizophrenia is a complex neuropsychiatric disorder. The etiology is not fully understood, but genetics plays an important role. Pathway analysis of genetic variants have suggested a central role for neuronal synaptic processes. Currently available antipsychotic medications successfully control positive symptoms (hallucinations and delusions) largely by inhibiting the dopamine D2 receptors; however, these drugs have more limited impact on negative symptoms (social withdrawal, flat affections, anhedonia) and cognitive deterioration. Drug development efforts have focused on a wide range of neurotransmitter systems and other agents, with conflicting or inconclusive results. New drug development paradigms are needed. A recent analysis, using common variant association results to match drugs based on their transcriptional perturbation signature, found drugs enriched in known antipsychotics plus novel candidates. We followed a similar approach, but started our analysis from a synaptic gene network implicated by rare copy number loss variants. We found that a significant number of antipsychotics (p-value = 0.0002) and other psychoactive drugs (p-value = 0.0004) upregulate synaptic network genes. Based on global gene expression similarity, active drugs formed two main clusters: one with many known antipsychotics and antidepressants, the other with various drug categories including two nootropics. We specifically recommend further examination of nootropics with limited side effects ( meclofenoxate , piracetam and vinpocetine ) for combination therapy with antipsychotics to improve cognitive performance. Detailed experimental follow-up is required to further evaluate other candidate drugs lacking an official nervous system indication, although, for at least a few of these, psychoactive effects have been reported in the literature.
INTRODUCTION
In this study, we followed a similar approach to So et al [So-NatNsc-2017] . However, we focused our analysis on the specific protein networks showing higher burden of rare copy number losses in schizophrenia patients compared to controls [PGC:CNV-NatGen-2017]. Variants causing loss-of-function by reducing dosage (such as rare copy number losses) are ideal for matching to transcriptional response signatures. Focusing on rare variants of large effects additionally ensures the presence of strong and clear biological effects. Moreover, adopting a network-informed approach enables to generalize beyond individual variants found in a few subjects while preserving biological specificity and thus addressing the problem of etiological heterogeneity in schizophrenia. We first confirmed that pre-constructed sets of drugs expected to be related to schizophrenia (antipsychotics and psychoactives) are over-represented in drugs with transcriptional effects remediating synaptic network rare losses, suggesting the validity of this strategy. We then investigated overall similarity relations among drugs, discovering two clusters of particular interest: one enriched in antipsychotics and antidepressants, the other with different drug categories including two nootropics. Based on these results, we specifically suggest the evaluation of nootropics with limited side effects to improve cognitive deficit. We also evaluated candidates without nervous system indications, finding evidence of psychoactive effects in the literature for at least some of them.
RESULTS

Synaptic gene networks enriched in rare copy number losses in schizophrenia
The Psychiatric Genomics Consortium (PGC) schizophrenia cohort of 21,094 cases and 20,227 controls with rare (at ≤ 1% frequency) copy number variants (CNVs) was previously analyzed for gene-set burden. That analysis identified a Gene Ontology (GO) derived set of synaptic components and the curated activity-regulated cytoskeleton-associated complex (ARC) as the most enriched in rare losses. Using the union of these two sets, a physical protein-protein interaction (ppi) network was seeded from genes passing an inclusive false discovery rate (FDR) threshold for locus-specific burden [PGC:CNV-NatGen-2017]. In addition to the original full network (which will be referred to as extended synaptic ), for this study we manually identified two nested subnetworks for the drug matching analysis: core synaptic and core glutamatergic ( see Figure 1 ). This was motivated by two main observations. First, the gene network presents particularly dense interactions around DLG1 (Discs large, drosophila, homolog of), including other postsynaptic scaffold organizers ( DLG2 , DLGAP1 , SHANK1 , SHANK2 ) and glutamatergic ionotropic receptors ( GRID1 , GRID2 , GRIN1 , GRIA4 ), all with excess losses in cases. In addition, the presynaptic adhesion gene NRXN1 (Neurexin 1), which is connected to the postsynaptic core by its trans-synaptic interaction with neuroligins, was also added to core glutamatergic (together with its immediate interaction neighbours) because it is important for glutamatergic synaptogenesis and maturation [Graf-2004-Cell] [Südhof-Nature-2008]. Second, the more sparsely-connected network periphery at the opposite end of DLG1 and NRXN1 is populated mostly by genes that belong to recurrent and large CNV loci. Contribution to schizophrenia risk for specific genes in this group is more uncertain, in spite of their synaptic function and the robust association of the multigenic CNV loci they belong to. For example, synaptic genes P2RX6 , SNAP29 and SEPT5 belong to the 22q11.21 deletion region. However, a network analysis of 22q11.21 deletion subjects with and without schizophrenia suggested copy number loss of CLTCL1 , P2RX6 , RTN4R and SEPT5 as more likely implicated in schizophrenia risk [Bassett-AmJPsy-2017 ]. In addition, SEPT5 , but not P2RX6 and SNAP29 , is predicted haploinsufficient based on genetic constraint [ExAC-2016-Nature] (ExAC pLI = 0.86, 5.8E-07 and 0.12 respectively, see also Figure 1 ). For this reason, genes in this peripheral region were excluded from the core synaptic network and retained only in the extended synaptic network. Using Gene Set Enrichment Analysis (GSEA) [GSEA-PNAS-2005], drugs were tested for enrichment in network gene upregulation, which corresponds to the opposite effect of copy number loss. For each network, we considered all network genes ( all ), or only network genes with excess losses in schizophrenia cases ( implicated , coloured in red or gold in Figure 2 ). Each drug thus received a GSEA normalized enrichment score (NES), p-value and BH-FDR for each synaptic network and for each gene selection (all, implicated). Drugs with positive NES for a given set of network genes display an enrichment of upregulation in those genes compared to others, and thus are presumed to have a beneficial effect ( see Supplementary Data Set 3 for detailed results). Based on GSEA enrichment results, drug categories were then tested for over-representation of drugs with positive NES, using Fisher's Exact Test. We tested psychoactive drugs removing antipsychotics and nervous system drugs removing psychoactive ones, to ensure that signal was not driven only by a small and specific subset of drugs within the larger one. Antipsychotics and other psychoactives displayed a robust over-representation in positive NES for the core synaptic network, and specifically for the implicated gene subset, with a non-significant trend towards a larger effect size in antipsychotics (antipsychotics, implicated: p-value = 0.00016, OR = 6.06; other psychoactives, implicated: p-value = 0.00036, OR = 3.61; see Figure 2 and Supplementary Table 1 ) . Over-representation results were similar for the extended synaptic network, but with a non-significant trend towards smaller effect sizes than core synaptic. The core glutamatergic network (implicated subset) displayed borderline significant over-representation for other psychoactives (p-value = 0.08144, OR = 1.77), but not for antipsychotics (p-value = 1, OR = 0.96). Other nervous system drugs did not display any significant over-representation (p-value > 0.1). Similar results were obtained when using a Wilcoxon rank-sum enrichment test instead of GSEA ( see Supplementary Figure 1 , Supplementary Table 2 and Supplementary Data Set 3 ). Setting more stringent enrichment thresholds (e.g. GSEA NES > 0 and BH-FDR < 25%) resulted in very large effect size confidence intervals and no significant over-representation, although effect size point estimates followed a trend similar to the main analysis (data not shown). Since over-representation results for the implicated gene subset were always better, we used this subset for all subsequent analyses. Over-representation in drugs with positive NES for the three pre-constructed drug categories (antipsychotics, other psychoactives and other nervous system), for each of the three nested synaptic networks (core glutamatergic, core synaptic, extended synaptic), when considering all network genes ( ALL ) or only genes with excess losses in schizophrenia subjects ( IMPLICATED , corresponding to red and gold genes in Figure 1 ). Odds-ratio point estimates are depicted as filled circles and 95% confidence intervals are depicted as vertical lines; the y axis presents odds-ratios in log2 scale, whereas text labels present odds-ratios in linear scale.
We further investigated drug category over-representation following a more unbiased approach. When considering ATC first-level categories (14, corresponding to organ systems), only core synaptic presented significant over-representation (FDR ≤ 10%), and only for nervous system drugs. When considering ATC second-level categories (93), only core synaptic presented significant over-representation, for psycholeptics and psychoanaleptics. When considering ATC third-level categories (267), again only core synaptic presented significant over-representation, for antipsychotics. To maximize power, we also tested only the subset of third-level categories that are nervous system drugs. Core synaptic was found significantly over-represented in antipsychotics, antidepressants (N06A, 28 drugs) and hypnotics and sedatives (N05C, 7 drugs), whereas core glutamatergic and extended synaptic did not present any significant over-representation at FDR ≤ 10%. Antiepileptics (N03A,10 drugs) and nootropics (N06B, 4 drugs) ranked in the top 5 for all three networks, but had borderline or insignificant nominal p-values and fairly high BH-FDR ( see Supplementary Data Set 4 ). Antipsychotics and psychoactive drugs presented a similar number of drug-treated samples and significantly up-regulated genes (BH-FDR ≤ 5%) compared to other drugs, suggesting over-representation is robust to variations in experimental design ( see Supplementary Table 3 ) . These results validated our choice of the pre-constructed drug categories relevant to schizophrenia, with a striking suggestion that most antipsychotics (at least partially) revert the effect of rare loss copy number variants on the synaptic networks.
Global similarity relations among drugs and prioritized drugs with nervous system activity
Drug similarity based on differential gene expression was quantified using Spearman correlation, followed by t-distributed stochastic neighbor embedding (t-SNE) projection to two dimensions for visualization [vanderMaaten-JMLR-2008] . When two drugs are in close proximity in the t-SNE plot, their differential profiles are expected to have a large and positive correlation. We manually identified two drug clusters over-represented in positive NES values for the core synaptic and core glutamatergic network (102 and 109 drugs respectively, see Figure 3a -b ). Similar results were obtained using a Jaccard similarity for DEGs with BH-FDR ≤ 5%, suggesting this analysis is robust to the choice of the similarity metric ( see Supplementary  Figure 2 ). We tested the two clusters for over-representation in first-, second-and third-level ATC categories. We found the first cluster strongly over-represented in antipsychotics (15/28, OR = 14.54, BH-FDR ≤ 1.5 10 -5 %) and antidepressants (9/28, OR = 5.57, BH-FDR ≤ 2.4%), but also in non-nervous system categories such as gynecological anti-infectives and antiseptics (ATC G01, 8/24, OR = 5.83, BH-FDR ≤ 2.4%), antifungals for dermatological use (ATC D01, 6/17, OR = 6.25, BH-FDR ≤ 7.2%) and non-selective calcium channel blockers for cardiovascular use (ATC C08E, 3/4, OR = 33.51, BH-FDR ≤ 8.1%). Interestingly, there was also a borderline significant under-representation in anti-infectives for systemic use (ATC J, OR = 0.31, BH-FDR ≤ 37%), specular to the over-representation in anti-infectives for topic use. This cluster was therefore labelled APAD (AntiPsychotics and AntiDepressants). The second cluster was not significantly over-represented in any category (at BH-FDR ≤ 10%), even when using different cluster boundaries. The most nominally significant nervous system sub-category was psychostimulants and nootropics (ATC N06B, 2/4, OR = 8.52, p-value = 0.0580), and thus the cluster was labelled MXNT (MiXed drugs and NooTropics) ( see Supplementary Data Set 5 ). Both clusters are over-represented in drugs with positive NES for the core glutamatergic and core synaptic network (APAD cluster: core glutamatergic p-value = 0.00258, OR = 1.89, core synaptic p-value = 4.31e-10, OR = 4.19; MXNT cluster: core glutamatergic p-value = 1.30e-11, OR = 3.85, core synaptic p-value = 2.38e-08, OR = 3.05). However, the APAD cluster, but not the MXNT cluster, displayed significantly smaller NES values for the glutamatergic network compared to core synaptic (APAD p-value = 8.06 10 -07 , MXNT p-value = 0.4880, Wilcoxon rank-sum test). Given the potential complementarity between antipsychotics and nervous system drugs inducing specific upregulation of the core glutamatergic network, we investigated various nervous system subcategories with some degree of over-representation in positive NES for core glutamatergic: none had a degree of clustering comparable to antipsychotics, antidepressants and nootropics ( see Supplementary Figure 3 ) . Figure 3 . Global similarity relations among drugs based on differential expression Spearman correlation and t-SNE dimensionality reduction. All plots represent the same drugs with the same coordinates, but graphically displaying different attributes and drug subsets. In panels (a-b) drugs are coloured based on core glutamatergic (a) or core synaptic (b) NES: magenta for positive NES (enrichment in upregulation), green for negative NES (enrichment in downregulation). In panels (c-f) drugs are coloured based on drug categories: antipsychotics in red, other psychoactives in purple, other nervous system in blue, other drugs in gray or black. In panels (c-e), drug labels are displayed when core synaptic NES > 0, in bold italic for the subset in which NES and log2FC are positive for all three networks and core synaptic BH-FDR < 50% (c: antipsychotics; d: other psychoactives; e: other nervous system drugs). In panel (f), because of the large number of drugs without nervous system indication, labels are displayed only when NES and log2FC are positive for all three networks and core synaptic BH-FDR < 33%. In all panels, the APAD drug cluster (over-represented in antipsychotics and antidepressants) is represented as a full yellow shade, whereas the MXNT cluster (miscellaneous drugs with borderline over-representation of nootropics) is represented as a lighter yellow shade.
The vast majority of typical antipsychotics categorized as phenothiazines are part of the APAD cluster (10/12, see Table 1 ), suggesting a strong correlation between chemical structure and differential expression response. The majority of phenothiazines also have positive core synaptic NES, but not at a higher rate than other antipsychotic chemical classes (8/10 phenothiazines, 14/16 other antipsychotics, Fisher's Exact Test p-value = 0.62542; see Table  1 ). The cluster also includes the powerful atypical clozapine , whereas the other two atypical antipsychotics, risperidone and remoxipride , map to different places ( see Figure 3c ). Other commonly used atypical antipsychotics ( aripiprazole , olanzapine , quetiapine ) are not represented in the CMap data-set. The antipsychotics benperidol (butyrophenone), levomepromazine and thioridazine (phenothiazines) have a positive effect on all three synaptic networks and pass a more stringent threshold for the core synaptic (positive NES and log2FC sum in all three networks and core synaptic GSEA BH-FDR < 50%, see Table 1 and Table 2 ). It is worth noting that the levomepromazine has a reputation of being a "dirty drug" because it interacts with a variety of targets and the branded version of thioridazine was withdrawn because it caused cardiac arrhythmias [Purhonen-PharmDrugSaf-2012] . While clozapine does not pass these thresholds, it is still remarkable that it has positive NES and log2FC sum for both core synaptic and core glutamatergic ( see Supplementary Data Set 3 ). In the 'All synaptic networks NES > 0 and log2FC sum > 0' column, 'yes*' indicates that the drug additionally has GSEA BH-FDR < 50% for the core synaptic network (these drugs have a bold italic font in Figure 3d ).
The APAD cluster also includes several antidepressants with positive core synaptic NES: the tricyclic antidepressants (TCA) amoxapine , desipramine , protriptyline , nortriptyline and trimipramine, and the specific serotonin reuptake inhibitors (SSRI) fluoxetine ( prozac ) and fluvoxamine ( see Figure 3d ). These drugs have in common the capability to inhibit serotonin reuptake, although TCAs also inhibit the reuptake of other neurotransmitters [Iversen- BrJPharm-2006] . TCAs have some degree of structural similarity to phenothiazines (the presence of two benzene rings), from which they were originally derived. The MXNT cluster contains two nootropics, meclofenoxate and piracetam , both with positive core synaptic and core glutamatergic NES ( see Figure 3d , Supplementary Data Set 3 Considering the other two nootropics outside the MXNT cluster, fipexide and vinpocetine , it is interesting to note that both have positive effects on all three synaptic networks and core synaptic BH-FDR < 50% ( see Table 2 ). In addition, while they are outside the MXNT cluster, they are in relative proximity ( see Figure 3d ) and they cluster more closely when using the Jaccard similarity ( see Supplementary Figure 2d ). Fipexide is a nootropic that was used for senile patients but later discontinued due to side effects such as liver necrosis [Bompani- CurrMedResOp-1986 ] [Durand- JHep-1992] . Vinpocetine use is not currently approved for clinical use, but preliminary findings relative to use for cognitive impairment and dementia are somewhat promising, with relatively limited side effects [Szatmari-Cochrane-2003 ]. Considering other MXNT cluster nervous system drugs, clomipramine and paracetamol have a positive effect on all three synaptic networks and core synaptic BH-FDR < 50% ( see Table 2 ). Clomipramine is a TCA additionally used to treat obsessive-compulsive disorder (OCD); it has a mild dopamine D1, D2 and D3 receptor antagonist activity, which is particularly interesting considering its proximity to the APAD cluster ( see Figure 3d ) Table 2 . Prioritized nervous system drugs: these drugs have positive NES and sum log2FC for all synaptic networks, and also core synaptic network GSEA BH-FDR < 50%. The label 'proposed' is used whenever a therapeutic indication has been proposed only by preliminary research works but is not well established. Drugs are sorted following the order in the main text (first by indication, then by cluster membership, then alphabetically).
Prioritized drugs without known nervous system activity
To identify top candidates lacking known nervous system activity, we set slightly more stringent criteria than for nervous system drugs: we required positive NES and sum log2FC in all synaptic networks plus core synaptic GSEA BH-FDR ≤ 33%. This resulted in 10 drugs, of which five are part of the MXNT cluster, two are not part but are in close proximity of MXNT cluster, and only one is part of the APAD cluster ( see Table 3 for details). Hesperidin is particularly interesting, as it was also reported in the schizophrenia GWAS drug repositioning analysis [So-NatNsc-2017] . Figure 2f ) ; primidone is an anticonvulsant barbiturate used in the past for seizures, which was also experimentally used for controlling aggression in psychotic patients [Monroe-JNervMentDis-1975] . Of other drugs, only alpha yohimbine and levamisole have known effects that could be of some interest to schizophrenia pharmacology ( see Table 3 Levamisole is an anthelmintic that exerts its action by stimulating ionotropic acetylcholine receptors and causing worm paralysis; it is currently used in veterinary medicine, but it was withdrawn from human use because of its side effects. It also exhibits a bland psychostimulant activity by inhibiting dopamine and norepinephrine reuptake, and its metabolite aminorex has a more pronounced psychostimulant effect [Hofmaier-NeurochemInt-2014] . Levamisole clusters with the analgesic nifenazone , but the two drugs do not appear to have similar pharmacological targets.
Drug Known pharmacological activity t-SNE cluster
0198306_0000
No information available None (near MXNT)
Alpha yohimbine Alpha-2-adrenergic blocking activity; used to reverse sedation in animals and to treat erectile dysfunction in humans; proposed for social anxiety treatment Table 3 . Top candidate drugs without nervous system activity, which have positive NES and sum log2FC for all synaptic networks and 'core synaptic' GSEA BH-FDR ≤ 33%. One of these studies also investigated very rare and disruptive variants from whole exome sequencing, finding convergent results with GWAS loci and suggesting these rare variants may be also implicated in antipsychotic resistance [Ruderfer-LancetPsy-2016] . However valuable, neither GWAS associations nor physical drug-protein interactions provide information on effect directionality. Reliance on physical drug-protein interactions can additionally limit results to already known and well-characterized pharmacological properties. To overcome these issues, a recent study used common variant association results to infer differential expression associated to schizophrenia risk; drugs were then prioritized for their capability to produce inverse differential expression patterns in cell line assays, thus modelling directionality at the drug and genetic effect level. Candidates found using this strategy were significantly enriched in antipsychotics, but also included other compounds that will need to be further investigated experimentally [So-NatNsc-2017] . We followed a similar approach, but started our analysis from a synaptic gene network implicated by rare copy number loss variants in schizophrenia patients compared to controls. -2016] . In addition to the full gene network (extended synaptic), we also considered two nested subnetworks (core synaptic and core glutamatergic) for our analysis. Similar to findings based on common variants [So-NatNsc-2017], we found antipsychotics to be over-represented in drugs leading to synaptic network up-regulation and thus reversing the rare loss effects. We found a similar trend for the other psychoactive drugs, including antidepressants, nootropics and anti-dementia drugs, but not for other nervous system drugs. This is an important initial proof-of-concept, further demonstrating the validity of using cell line transcriptional perturbation signatures for pharmacology of CNS conditions. We then investigated global similarity relations between drugs: we think this is a critical step to differentiate therapeutic opportunities that mimic the effect of antipsychotics or that act differently and thus may have a synergistic effect. We identified two major clusters: (1) APAD, strongly over-represented in antipsychotics (and specifically phenothiazines), but also antidepressants and other drugs; (2) MXNT, without any specific over-representation, but including two nootropics and other nervous system drugs. While clustering patterns (at least partially) reflect the known pharmacology, they also suggest the existence of more complex mechanisms: for instance, 9/24 antipsychotics with positive effects on the core synaptic network are not member of the APAD cluster, suggesting they induce different global transcriptional effects. The over-representation in antipsychotics but also antidepressants for the APAD cluster is intriguing, since schizophrenia presents a high genetic correlation to bipolar disorder and depression [Bulik-Sullivan-NatGen Transcriptional perturbation signatures are used as proxy of cell state: additionally measuring neuronal cell phenotypes (like nervous signal transmission and synaptic formation or pruning) would be highly beneficial, but would also require a major experimental effort to test a sufficiently large number of drugs. A more fundamental challenge is posed by the heterogeneous etiology of schizophrenia and the reliance, as a nosological construct, on clinical consensus rather than more mechanistic and biologically-rooted criteria. Developing experimental models of its key pathological processes, whether using human brain organoids or model organisms, is probably going to be one of the major challenges on the way towards successful drug discovery [Keshavan-ProgNeurob-2017]. We argue that variants of large effect that are able to recapitulate the disease and its known pharmacology in experimental models, such as the rare copy number losses in the synaptic networks described in this work, constitute a particularly valuable resource towards this goal.
DISCUSSION
METHODS
CMap gene expression data
The expression signatures were downloaded from the cmap database: https://portals.broadinstitute.org/cmap/ . The full data-set consists of 7056 CEL files corresponding to three different array platforms (807 for HG-U133A, 6029 for HT_HG-U133A and 220 for HT_HG-U133A_EA). To avoid between array normalization, this study focused on the drugs profiled on the HT_HG-U133A platform, comprising a total of 5,242 treated and 787 untreated samples tested on three different cell lines (MCF7, PC3, HL60). The CEL files were imported using the R/Bioconductor affy package v1.54.0 and probe-set level gene expression summaries, normalized between samples, were generated using the rma method 
Differential gene expression analysis
For each drug, the following generalized linear model was fit using the R/Bioconductor package limma v3.32.10 [Ritchie-NAR-2015]: Expr = b1 * combinedFactor + b2 * treatment + b3 * combinedFactor * treatment where combinedFactor corresponds to the combined values of the cell line used for screening, the drug dose and the response time after treatment. Differential expression p-values and log2 fold-change (FC) were calculated based on the b2 coefficient.
GSEA and Wilcoxon enrichment analysis
First, differential gene expression results were processed to convert probe-set identifiers to gene identifiers (NCBI Entrez-Gene), using the mapping table from the R/Bioconductor package hthgu133a.db v3.2.3. In presence of multiple probe-sets mapping to to the same single entrez gene id, only the most most differentially expressed probe-set was retained. Then, for each drug, GSEA pre-ranked version 3.0 (using default weighting) was used to analyze synaptic network enrichment in upregulation, providing in input genes ranked by limma moderated t-statistic (equivalent to ranking by -log10 (p-value) * sign (log2 FC)) and 6 gene-sets corresponding to each combination of network (core glutamatergic, core synaptic, extended synaptic) and gene subset (all, implicated). GSEA enrichment p-values were corrected for multiple testing using BH-FDR for each combination separately, across all drugs. For the Wilcoxon enrichment analysis, the GSEA pre-ranked test was replaced by a two-sided Wilcoxon rank-sum test as implemented in the R function wilcox.test() ; the GSEA NES was replaced by an enrichment score (ES) calculated as the difference of the average of the gene inverse ranks for the gene-set and the other genes (where an inverse rank for N values is N for the largest value and 1 for the smallest); multiple test correction by BH-FDR was performed following the same logic as for the GSEA enrichment analysis.
Drug category over-representation
Drug category over-representation in drugs with positive NES drugs and in drugs within t-SNE clusters was performed using a two-sided Fisher's Exact Test as implemented by the R function fisher.test() ; given a network of interest, the contingency matrix was defined as: (a) number of drugs within category (or within cluster) and NES > 0, (b) number of drugs within category (or within cluster) and NES < 0, (a) number of drugs outside the category (or outside the cluster) and NES > 0, (b) number of drugs outside the category (or outside the cluster) and NES < 0.
Multiple test correction using BH-FDR
BH-FDR multiple test correction was performed using the R function p.adjust(method = "BH") .
t-SNE dimensionality reduction
Differential expression data was first converted to a similarity matrix using the Spearman correlation between limma moderated t-statistic vectors, calculated using the R function cor(method = "spearman") . The same analysis was repeated using as similarity the Jaccard index between sets of differentially expressed genes at BH-FDR < 5%, averaging for every drug the Jaccard index separately calculated for upregulated and downregulated genes. The similarity matrix was used to derived the 2d projection using to the tsne() function in the tsne R/CRAN package v0. 1-3. [vanderMaaten-JMLR-2008] 
